Biogen Inc BIIB:NASDAQ (Common Stock)

LastDaily Change / % ChangeDividend YieldVolumeAvg Volume (10 day)
342.42 -2.16   -0.63%--81.3M
Market data is delayed by at least 15 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Previous close 10/19/2017 (03:59 PM 10/19/2017 Eastern Standard Time)

Latest News Headlines for Biogen Inc

Biogen Confirms Commitment to Tackle Multiple Sclerosis Through Comprehensive Approach

IR@biogen.com SOURCE: Biogen Copyright Business Wire 2017 (END) Dow Jones Newswires October 18, 2017 07:30 ET (11:30 GMT)

View more recent headlines

Peers Information HelpBIIB Biogen Inc vs. Peers

BIIB
Biogen Inc
31.09%
-9.88%
Allergan plc
Celgene Corporation
17.46%
-13.24%
Shire PLC (ADR)
Mylan NV
0.37%
BIIB
Biogen Inc
0.00%
Allergan plc
1.48%
Celgene Corporation
0.00%
Shire PLC (ADR)
0.62%
Mylan NV
0.00%
-0.63%
BIIB
Biogen Inc
Allergan plc
1.13%
-0.88%
Celgene Corporation
Shire PLC (ADR)
1.05%
Mylan NV
2.08%
Compare these stocks

Latest Annual and Quarterly SEC Filings

More Filings
10-K

This report contains detailed information about the company's business finances and management.

10-Q

Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.

https://www.biogen.com/

Loading...

collapse, right-facing arrow indicating collapsed view of sectionOverview

A table providing an overview of the stock
Bid | Size-- | --
Ask | Size-- | --
Price Open343.40
Previous Close342.42
Day High346.11
Day Low338.11
52 Week High10/18/2017 | 348.84
52 Week Low5/31/2017 | 244.28
% Off 52 Week High-1.84%
% Off 52 Week Low40.18%
Beta (5 Yr)0.7
Volatility Avg10/19/2017 | 24.92
10-Day Avg. Volume1,259,668
Market data is delayed by at least 15 minutes.

collapse, right-facing arrow indicating collapsed view of sectionFundamentals

A table providing the fundamentals of the stock
EPS (TTM)6/30/2017 | 15.23
P/E Ratio6/30/2017 | 22.5
Market CapLarge Cap | 72.40B
Shares Outstanding211.43M
Float210.6M

collapse, right-facing arrow indicating collapsed view of sectionDividends

A table providing information about the dividends of the stock
Dividend Yield--
Ex-Date--
Dividend Announcement--
Date of Record--
Payable-- - --
Payable Date--

collapse, right-facing arrow indicating collapsed view of sectionShare Statistics

A table providing statistics about shares of the stock
Shares Short3.76M
Short Ratio2.5
Short % of Float1.79%
As of 9/15/2017
The performance data quoted represents past performance. Past performance does not guarantee future results. Current performance may be lower or higher than the performance quoted. Investment return and principal value of an investment will fluctuate and when redeemed, the investment may be worth more or less than their original cost.
The research, tools, and information provided will not include every security available to the public.